COVID 19: Government Relief Programs for Life Science Companies
- Mar 19, 2020
- John Pennett
Owing to the COVID-19 crisis, companies are finding themselves under duress. Issues range from supply chain disruption, altered work arrangements and patterns, reduction of non-essential medical procedures, expected tightened public and private capital sourcing, and more.
In response, the U.S. federal and some state governments are beginning to consider or offer relief in the form of tax payment holidays, expedited regulatory processes, and some direct aid in the form of loans. The federal government is also exploring a plan to give Americans billions in direct payments, similar to 2008. There is also discussion of potentially invoking the Defense Production Act, which will allow the administration to direct factories to produce more face masks, gowns, gloves and other critical medical supplies.
As an example, the Small Business Administration has a disaster recovery plan. Once a disaster declaration is formally established, small businesses could apply for a loan of up to $2 million at a 3.75% interest rate and nonprofit organizations at 2.75% for a timeframe of up to 30 years (all individually negotiated). For more specific details on the loan programs, contact your local SBA office.
What's on Your Mind?
John Pennett is the Partner-in-Charge of the National Technology and Life Sciences Group and works closely with our IPO clients and their circle of legal and underwriting advisors to take an IPO from concept to close.
Start a conversation with John
Explore More Insights
It's Not You, It's Your Software | Embracing the Future as a Digital CFORead More
Proposed Regulations for Determining Proceeds, Basis, and Reporting Requirements for Digital AssetsRead More
Receive the latest business insights, analysis, and perspectives from EisnerAmper professionals.